The significance of α-defensins 1-3 in Behcet’s disease: a case-control study among Egyptian patients

Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behcet’s disease. N Engl J Med 341:1248–1291 Yazici H, Fresko I, Yurdakul S (2007) Behcet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 3:148–155 Direskeneli H (2001) Behcet’s disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 60:996–1002 Ganz T (2003) Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 3:710–720 Ouellette AJ, Darmoul D, Tran D, Huttner KM, Yuan J, Selsted ME (1999) Peptide localization and gene structure of cryptdin 4, a differentially expressed mouse paneth cell alpha-defensin. Infect Immun 67(12):6643–6651 PMC 97078. PMID 10569786 Nassar H, Lavi E, Akkawi S, Bdeir K, Heyman SN, Raghunath PN, Tomaszewski J, Higazi AA (2007) alpha-Defensin: link between inflammation and atherosclerosis. Atherosclerosis. 194(2):452–457 Yang D, Biragyn A, Hoover DM, Lubkowski J, Oppenheim JJ (2004) Multiple roles of antimicrobial defensins, cathelicidins, and eosionphil-derived neurotoxin in host defence. Annu Rev Immunol 22:181–215 Vordenbäumen S, Fischer-Betz R, Timm D, Sander O, Chehab G, Richter J, Bleck E, Schneider M (2010) Elevated levels of human beta-defensin 2 (hbd2) and human neutrophil peptides (hnp) in systemic lupus erythematosus. Lupus 19(14):1648–1653 Mukae H, Matsumoto N, Ashitani J, Mahimoto H, Kadota J, Nakazato M, Kohno S, Matsukura S (1996) Neutrophil-related cytokines and neutrophil products in bronchoalveolar lavage fluid. Eur Respir J 9:1950–1954 Tamiya H, Tani K, Miyata J, Sato K, Urata T, Lkhagvaa B, Otsuka S, Shigekiyo S, Sone S (2006) Defensin-and cathepsin G-ANCA in systemic lupus erythematosus. Rheumatol Int 27:147–152 Srivastava MD, Alexander F, Tuthill RJ (2005) Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol 61:329–336 Quinn K, Henriques M, Parker T, Slutsky AS, Zhang H (2008) Human neutrophil peptides: a novel potential mediator of inflammatory cardiovascular diseases. Am J Physiol Heart Circ Physiol 295:H1817–H1824 Becker K, Fitzgerald O, Green AJ, Keogan M, Newbury-Ecob R, Greenhalgh L et al (2009) Constitutional trisomy 8 and Behcet syndrome. Am J Med Genet A 149A:982 Mertens D, Gunaydin I, Fresko I, Yazici H, Mueller C (2004) Expression of alpha defensins HNP-1 in Behcet’s disease: effector molecules of spontaneous and pathergy induced papulopustular lesions. Clin Exp Rheumatol 22(Suppl.34):93 Mumcu G, Cimilli H, Karacayli U, Inanc N, Ture-Ozdemir F, Eksioglu-Demiralp E et al (2012) Salivary levels of antimicrobial peptides Hnp1-3, LI-37 and S100 in Behcet’s disease. Arch Oral Biol 57:642–646 Omma A, Sandikci SC, Colak S, Tecer D, Yucel C, Ozbalkan Z (2018) Serum calprotectin and ischemia modified albumin levels as markers of disease activity in Behçet’s disease. Postepy Dermatol Alergol 35(6):609–613 International Team for the Revision of the International Criteria for Behcet’s Disease (2014) The International Criteria for Behcet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28:338–347 Yilmaz S, Simsek I, Cinar M, Erdem H, Kose O, Yazici Y et al (2013) Patient-driven assessment of disease activity in Behcet’s syndrome: cross-cultural adaptation, reliability and validity of the Turkish version of the Behcet’s Syndrome Activity Score. Clin Exp Rheumatol 31:77–83 Krause I, Mader R, Sulkes J, Paul M, Uziel Y, Adawi M et al (2001) Behcet’s disease in Israel: the influence of ethnic origin on disease expression and severity. J Rheumatol 28:1033–1036 Mumcu G, Sur H, Inanc N, Karacayli U, Cimilli H, Sisman N et al (2009) A composite index for determining the impact of oral ulcer activity in Behcet’s disease and recurrent aphthous stomatitis. J Oral Pathol Med 38:785–791 Ahn JK, Hwang J, Oh JM, Bae EK, Lee J, Lee YS et al (2011) Increased α-defensin-1 expression in Korean patients with Behcet’s disease. Joint Bone Spine 78:593–597 Bokarewa MI, Jin T, Tarkowski A (2003) Intraarticular release and accumulation of defensins and bactericidal/permeability-increasing protein in patients with rheumatoid arthritis. J Rheumatol 30:1719–1724 Ahn JK, Cha H-S, Lee J, Jeon CH, Koh E-M (2012) Correlation of DEFA1 gene copy number variation with intestinal involvement in Behcet’s disease. J Korean Med Sci 27(1):107–109 Kucukkolbasi H, Kucukkolbasi S, Dursun R, Ayyildiz F, Kara H (2011) Determination of defensin HNP-1 in human saliva of patients with oral mucosal diseases. J Immunoass Immunochem 32:284–295 Gomes Pde S, Fernandes MH (2010) Defensins in the oral cavity: distribution and biological role. J Oral Pathol Med 39:1–9 Pay S, Simsek I, Erdem H, Dinc A (2007) Immunopathogenesis of Behcet’s disease with special emphasize on the possible role of antigen presenting cells. Rheumatol Int 27:417–424 Ugurel E, Erdag E, Kucukali Cİ, Olcay A, Sanli E et al (2019) Enhanced NLRP3 and DEFA1B expression during the active stage of parenchymal neuro-Behçet’s disease. In Vivo 33(5):1493–1497 Katsantonis J, Adler Y, Orfanos CE, Zouboulis CC (2000) Adamantiades-Behcet’s disease: serum IL8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology 201:37–39 Brook M, Tomlinson GH, Miles K, Smith RW, Rossi AG, Hiemstra PS et al (2016) Neutrophil-derived alpha defensins control inflammation by inhibiting macrophage mRNA translation. Proc Nati Acad Sci USA 113:4350–4355